LT3696B - Oral composition for the treatment of inflammatory bowel diseases - Google Patents

Oral composition for the treatment of inflammatory bowel diseases Download PDF

Info

Publication number
LT3696B
LT3696B LTIP1751A LTIP1751A LT3696B LT 3696 B LT3696 B LT 3696B LT IP1751 A LTIP1751 A LT IP1751A LT IP1751 A LTIP1751 A LT IP1751A LT 3696 B LT3696 B LT 3696B
Authority
LT
Lithuania
Prior art keywords
epimer
butylidenedioxy
dione
water
diene
Prior art date
Application number
LTIP1751A
Other languages
English (en)
Lithuanian (lt)
Inventor
Jan Ulmius
Original Assignee
Draco Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3696(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Draco Ab filed Critical Draco Ab
Publication of LTIP1751A publication Critical patent/LTIP1751A/xx
Publication of LT3696B publication Critical patent/LT3696B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines Containing Plant Substances (AREA)
LTIP1751A 1989-11-22 1993-12-31 Oral composition for the treatment of inflammatory bowel diseases LT3696B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8903914A SE8903914D0 (sv) 1989-11-22 1989-11-22 Oral composition for the treatment of inflammatory bowel diseases

Publications (2)

Publication Number Publication Date
LTIP1751A LTIP1751A (en) 1995-07-25
LT3696B true LT3696B (en) 1996-02-26

Family

ID=20377544

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP1751A LT3696B (en) 1989-11-22 1993-12-31 Oral composition for the treatment of inflammatory bowel diseases

Country Status (36)

Country Link
US (1) US6423340B1 (id)
EP (1) EP0502092B1 (id)
JP (1) JP3145111B2 (id)
KR (1) KR0179042B1 (id)
AT (1) ATE125445T1 (id)
AU (1) AU643021B2 (id)
CA (1) CA2071518C (id)
DE (1) DE69021214T2 (id)
DK (1) DK0502092T3 (id)
EG (1) EG19642A (id)
ES (1) ES2074698T3 (id)
FI (2) FI104949B (id)
GR (1) GR3017691T3 (id)
HK (1) HK51897A (id)
HR (1) HRP920632B1 (id)
HU (2) HU216836B (id)
IE (1) IE74854B1 (id)
IL (1) IL96415A (id)
IS (1) IS1858B (id)
LT (1) LT3696B (id)
LV (1) LV10183B (id)
MY (1) MY104535A (id)
NO (1) NO304010B1 (id)
NZ (1) NZ235807A (id)
PL (1) PL166506B1 (id)
PT (1) PT95946A (id)
RU (1) RU2134104C1 (id)
SA (1) SA90110123B1 (id)
SE (1) SE8903914D0 (id)
SG (1) SG54210A1 (id)
SI (1) SI9012150A (id)
TW (1) TW250435B (id)
UA (1) UA37196C2 (id)
WO (1) WO1991007172A1 (id)
YU (1) YU48583B (id)
ZA (1) ZA908777B (id)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
WO1994015947A1 (en) * 1993-01-08 1994-07-21 Astra Aktiebolag Novel colon- or ileum-specific steroid derivatives
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4332394A1 (de) * 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
KR20000053327A (ko) * 1996-11-15 2000-08-25 데이비드 엠 모이어 결장내 운반에 사용되는 약학적 제형
SE9604751D0 (sv) 1996-12-20 1996-12-20 Astra Ab New therapy
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6239120B1 (en) 1998-03-17 2001-05-29 Pharmalink Ab Method and means for treating glomerulonephritis
GB9824604D0 (en) 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
SE9902673D0 (sv) * 1999-07-12 1999-07-12 Astra Ab New composition
WO2002074316A1 (en) * 2001-03-15 2002-09-26 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
DK1572217T3 (da) 2002-12-12 2008-12-15 Nycomed Gmbh Kombinationsmedikament af R,R-formoterol og ciclesonid
EP1607087A1 (en) * 2003-03-27 2005-12-21 Hisamitsu Pharmaceutical Co., Inc. Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
CA2538202C (en) * 2003-09-15 2013-01-15 Altana Pharma Ag Use of ciclesonide for the treatment of inflammatory bowel diseases
ES2452691T5 (es) 2003-09-16 2022-09-14 Covis Pharma Gmbh Uso de ciclesonida para el tratamiento de enfermedades respiratorias
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
WO2007056539A2 (en) * 2005-11-08 2007-05-18 Medarex, Inc. Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
CA2684655A1 (en) * 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. Oral pharmaceutical preparation for colon-specific delivery
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
EA022886B1 (ru) * 2008-10-03 2016-03-31 Др. Фальк Фарма Гмбх Способ поддержания ремиссии язвенного колита у пациентов
US8945616B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
US8945615B2 (en) 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
CA2826662A1 (en) * 2011-02-04 2012-08-09 Optimer Pharmaceuticals, Inc. Treatment of bacterial infections
MD480Z5 (ro) * 2011-07-07 2012-09-30 Эльвира АНДОН Metodă de tratament al colitei ulceroase nespecifice acute
RS56839B1 (sr) 2012-04-30 2018-04-30 Tillotts Pharma Ag Formulacija leka sa odloženim otpuštanjem
US10799515B2 (en) 2013-10-29 2020-10-13 Tillotts Pharma Ag Delayed release drug formulation
RU2018111690A (ru) * 2015-09-11 2019-10-11 Сан Фармасьютикл Индастриз Лтд. Пероральная лекарственная форма будесонида
CN105663091A (zh) * 2016-01-28 2016-06-15 上海信谊百路达药业有限公司 一种布地奈德肠溶缓释胶囊及其制备方法
WO2017138877A1 (en) * 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601745B (zh) * 2016-02-09 2021-12-07 阿尔比里奥公司 口服考来烯胺制剂及其用途
EP3613414A1 (de) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996356A (en) 1969-07-02 1976-12-07 Hoffmann-La Roche Inc. Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine
SE378109B (id) 1972-05-19 1975-08-18 Bofors Ab
SE7813246L (sv) 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
SE8008524L (sv) 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
SE8306370D0 (sv) 1983-11-18 1983-11-18 Draco Ab Novel androstane-17beta-carboxylic acid esters, a process and intermediates for their preparation, compositions and method for the treatment of inflammatory conditions
US4708867A (en) 1983-12-19 1987-11-24 Key Pharmaceuticals, Inc. Minipellets
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
DE3536267A1 (de) 1985-10-11 1987-04-16 Bayer Ag Azofarbstoffe sowie fluessigkristallines material enthaltend azofarbstoffe
SE8506015D0 (sv) 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
GB8630913D0 (en) * 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US4966770A (en) 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
DE10307386A1 (de) 2003-02-21 2004-09-09 Dieter Wildfang Gmbh Verfahren zum außenseitigen Beschichten eines sanitären Auslaufteiles sowie sanitäres Auslaufteil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. WOLMAN: "Panaudojimas orlainio budezonido plonųjų žarnų Krono ligos ir antrinių smegenų pseudonaviko, atsiradusio po steroidų panaudojimo, gydymui", GASTROENTEROL

Also Published As

Publication number Publication date
IS3644A7 (is) 1991-05-23
UA37196C2 (uk) 2001-05-15
DE69021214T2 (de) 1996-01-04
FI19991893A (fi) 1999-09-06
HRP920632A2 (en) 1995-04-30
EG19642A (en) 1995-08-30
AU7786491A (en) 1991-06-13
DK0502092T3 (da) 1995-12-27
HU9201700D0 (en) 1992-08-28
HUT60630A (en) 1992-10-28
LV10183B (en) 1995-08-20
ZA908777B (en) 1991-07-31
LV10183A (lv) 1994-10-20
SA90110123B1 (ar) 1999-06-06
KR920703025A (ko) 1992-12-17
SI9012150A (sl) 1998-08-31
IL96415A (en) 1995-11-27
YU215090A (sr) 1996-01-09
IE74854B1 (en) 1997-08-13
MY104535A (en) 1994-04-30
EP0502092A1 (en) 1992-09-09
HK51897A (en) 1997-05-02
IS1858B (is) 2003-03-27
PL287844A1 (en) 1991-12-02
RU2134104C1 (ru) 1999-08-10
LTIP1751A (en) 1995-07-25
FI922325A0 (fi) 1992-05-21
NO304010B1 (no) 1998-10-12
CA2071518C (en) 2002-11-12
NZ235807A (en) 1993-02-25
ES2074698T3 (es) 1995-09-16
NO922004D0 (no) 1992-05-21
GR3017691T3 (en) 1996-01-31
NO922004L (no) 1992-05-21
ATE125445T1 (de) 1995-08-15
FI922325A (fi) 1992-05-21
IE904170A1 (en) 1991-05-22
TW250435B (id) 1995-07-01
EP0502092B1 (en) 1995-07-26
PL166506B1 (pl) 1995-05-31
FI104949B (fi) 2000-05-15
KR0179042B1 (ko) 1999-03-20
IL96415A0 (en) 1991-08-16
SE8903914D0 (sv) 1989-11-22
JP3145111B2 (ja) 2001-03-12
AU643021B2 (en) 1993-11-04
HRP920632B1 (en) 1999-10-31
YU48583B (sh) 1998-12-23
US6423340B1 (en) 2002-07-23
HU216836B (hu) 1999-09-28
PT95946A (pt) 1991-09-13
WO1991007172A1 (en) 1991-05-30
SG54210A1 (en) 1998-11-16
DE69021214D1 (de) 1995-08-31
CA2071518A1 (en) 1991-05-23
JPH05501705A (ja) 1993-04-02

Similar Documents

Publication Publication Date Title
LT3696B (en) Oral composition for the treatment of inflammatory bowel diseases
US5643602A (en) Oral composition for the treatment of inflammatory bowel disease
CA1302262C (en) Pharmaceutical composition containing flutiasone propionate
RU2435568C2 (ru) Таблетки с высвобождением активного ингредиента, происходящим в определенном месте и в определенное время
JP2002080398A (ja) ｐＨに依存する多相的な放出を伴う経口用の固体の薬学的組成物
KR20090122489A (ko) 결장-특이적 전달을 위한 경구적 약제학적 제제
JP3469926B2 (ja) 大腸内放出型医薬製剤用粒状物
JP5371189B2 (ja) 炎症性腸疾患の治療のためのシクレソニドの使用
WO1998018474A1 (de) Verwendung von ursodeoxycholsäure zur topischen behandlung von entzündungserkrankungen der schleimhäute
EP1100481B1 (en) Pharmaceutical formulations comprising beclomethasone dipropionate for the treatment of inflammatory bowel disease
SE514128C2 (sv) Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit
PT876142E (pt) Aplicacao topica de farmacos no tracto gastrointestinal inferior
WO1994007503A1 (en) Enteric preparations

Legal Events

Date Code Title Description
MK9A Expiry of a patent

Effective date: 20131231